Rapid Micro Biosystems (RPID)
Market Price (7/13/2026): $2.1 | Market Cap: $94.7 MilSector: Health Care | Industry: Life Sciences Tools & Services
Rapid Micro Biosystems (RPID)
Market Price (7/13/2026): $2.1Market Cap: $94.7 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Automation & Robotics. Themes include Biopharmaceutical R&D, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -47 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -141% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -92%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -95% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% Key risksRPID key risks include [1] its significant cash burn and uncertain path to profitability, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -16% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -36% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Automation & Robotics. Themes include Biopharmaceutical R&D, Show more. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -47 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -141% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -92%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -95% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -55% |
| Key risksRPID key risks include [1] its significant cash burn and uncertain path to profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Rapid Micro Biosystems (RPID) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Disappointing Fiscal Q1 2026 Earnings. Rapid Micro Biosystems, whose fiscal year ends December 31, reported its fiscal Q1 2026 results (ending March 31, 2026) on May 13, 2026, revealing a net loss of $0.31 per share. This significantly missed the analyst consensus estimate of -$0.2516 by 23.21%. While total revenue grew 11.1% year-over-year to $8.0 million, the wider-than-expected net loss raised investor concerns regarding the company's path to profitability.
2. Dilutive Public Offering of Securities. In May 2026, Rapid Micro Biosystems announced the pricing of an underwritten public offering of its Class A common stock and accompanying Series A and Series B warrants. This offering, which was expected to generate approximately $9.8 million in gross proceeds, likely contributed to share dilution and exerted downward pressure on the stock price. The offering was priced at $1.955 per share on May 19, 2026, reflecting a significant drop in valuation from earlier in the quarter.
Show more
Rapid Micro Biosystems (RPID) stock has lost about 10% since 3/31/2026 because of the following key factors:
1. Disappointing Fiscal Q1 2026 Earnings. Rapid Micro Biosystems, whose fiscal year ends December 31, reported its fiscal Q1 2026 results (ending March 31, 2026) on May 13, 2026, revealing a net loss of $0.31 per share. This significantly missed the analyst consensus estimate of -$0.2516 by 23.21%. While total revenue grew 11.1% year-over-year to $8.0 million, the wider-than-expected net loss raised investor concerns regarding the company's path to profitability.
2. Dilutive Public Offering of Securities. In May 2026, Rapid Micro Biosystems announced the pricing of an underwritten public offering of its Class A common stock and accompanying Series A and Series B warrants. This offering, which was expected to generate approximately $9.8 million in gross proceeds, likely contributed to share dilution and exerted downward pressure on the stock price. The offering was priced at $1.955 per share on May 19, 2026, reflecting a significant drop in valuation from earlier in the quarter.
3. Persistent Pressure from Weak Gross Margins and Elevated Operating Expenses. For fiscal Q1 2026, the company's gross margin remained low at 4.6%. Concurrently, total operating expenses increased by 17.9% year-over-year, reaching $14.2 million. This rise was primarily driven by a 30.8% increase in general and administrative expenses and a 24.4% increase in sales and marketing expenses, indicating ongoing operational challenges in achieving profitability despite revenue growth.
4. Challenging Market Sentiment for Growth-Stage Biotechnology Companies. During fiscal Q2 2026, the broader biotechnology sector experienced a divergence in performance, with lower-tier equities facing consistent declines. Investors increasingly prioritized established assets over more speculative ventures. As a pre-profitable growth company, Rapid Micro Biosystems likely faced significant headwinds from this shift in market sentiment, contributing to its stock's underperformance.
Show less
Stock Movement Drivers
Fundamental Drivers
The -9.7% change in RPID stock from 3/31/2026 to 7/12/2026 was primarily driven by a -9.7% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.27 | 2.05 | -9.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 34 | 34 | 0.0% |
| P/S Multiple | 3.0 | 2.8 | -9.7% |
| Shares Outstanding (Mil) | 45 | 45 | 0.0% |
| Cumulative Contribution | -9.7% |
Market Drivers
3/31/2026 to 7/12/2026| Return | Correlation | |
|---|---|---|
| RPID | -9.7% | |
| Market (SPY) | 16.1% | 28.7% |
| Sector (XLV) | 9.7% | 8.1% |
Fundamental Drivers
The -29.3% change in RPID stock from 12/31/2025 to 7/12/2026 was primarily driven by a -35.5% change in the company's P/S Multiple.| (LTM values as of) | 12312025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.90 | 2.05 | -29.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 31 | 34 | 10.0% |
| P/S Multiple | 4.3 | 2.8 | -35.5% |
| Shares Outstanding (Mil) | 45 | 45 | -0.3% |
| Cumulative Contribution | -29.3% |
Market Drivers
12/31/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| RPID | -29.3% | |
| Market (SPY) | 11.0% | 29.2% |
| Sector (XLV) | 4.3% | 19.6% |
Fundamental Drivers
The -40.6% change in RPID stock from 6/30/2025 to 7/12/2026 was primarily driven by a -46.2% change in the company's P/S Multiple.| (LTM values as of) | 6302025 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.45 | 2.05 | -40.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 34 | 13.3% |
| P/S Multiple | 5.1 | 2.8 | -46.2% |
| Shares Outstanding (Mil) | 44 | 45 | -2.5% |
| Cumulative Contribution | -40.6% |
Market Drivers
6/30/2025 to 7/12/2026| Return | Correlation | |
|---|---|---|
| RPID | -40.6% | |
| Market (SPY) | 23.2% | 27.5% |
| Sector (XLV) | 20.9% | 21.5% |
Fundamental Drivers
The 105.0% change in RPID stock from 6/30/2023 to 7/12/2026 was primarily driven by a 86.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 6302023 | 7122026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.00 | 2.05 | 105.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 18 | 34 | 86.5% |
| P/S Multiple | 2.4 | 2.8 | 15.8% |
| Shares Outstanding (Mil) | 43 | 45 | -5.1% |
| Cumulative Contribution | 105.0% |
Market Drivers
6/30/2023 to 7/12/2026| Return | Correlation | |
|---|---|---|
| RPID | 105.0% | |
| Market (SPY) | 76.3% | 22.7% |
| Sector (XLV) | 26.9% | 20.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RPID Return | -50% | -89% | -35% | 22% | 222% | -40% | -92% |
| Peers Return | 37% | -22% | 1% | -10% | 4% | -4% | -2% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| RPID Win Rate | 33% | 8% | 42% | 58% | 50% | 43% | |
| Peers Win Rate | 72% | 37% | 50% | 40% | 52% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 57% | |
Max Drawdowns [4] | |||||||
| RPID Max Drawdown | - | -90% | -51% | -45% | -49% | -65% | |
| Peers Max Drawdown | -18% | -35% | -30% | -25% | -37% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, BDX, CRL, RGEN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/10/2026 (YTD)
How Low Can It Go
| Event | RPID | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -46.8% | -18.8% |
| % Gain to Breakeven | 87.9% | 23.1% |
| Time to Breakeven | 56 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -10.1% | -9.5% |
| % Gain to Breakeven | 11.2% | 10.5% |
| Time to Breakeven | 6 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.2% | -6.7% |
| % Gain to Breakeven | 56.6% | 7.1% |
| Time to Breakeven | 624 days | 31 days |
In The Past
Rapid Micro Biosystems's stock fell -46.8% during the 2025 US Tariff Shock. Such a loss loss requires a 87.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | RPID | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -46.8% | -18.8% |
| % Gain to Breakeven | 87.9% | 23.1% |
| Time to Breakeven | 56 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.2% | -6.7% |
| % Gain to Breakeven | 56.6% | 7.1% |
| Time to Breakeven | 624 days | 31 days |
In The Past
Rapid Micro Biosystems's stock fell -46.8% during the 2025 US Tariff Shock. Such a loss loss requires a 87.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Rapid Micro Biosystems (RPID)
Rapid Micro Biosystems (RPID) is a life sciences technology company focused on providing solutions for the detection of microbial contamination. The company's primary goal is to help manufacturers, particularly within the pharmaceutical, medical device, and personal care product sectors, ensure product safety and quality. It achieves this by automating and modernizing the traditionally manual processes involved in microbial quality control (MQC) testing.
The core of RPID's offerings is its proprietary Growth Direct platform. This comprehensive system comprises the Growth Direct instrument, specialized consumables, software for integrating with lab information management systems (LIMS), and extensive customer support and validation services. The platform significantly enhances efficiency and accelerates critical test results by automating MQC workflows for various therapeutic modalities, including biologics, vaccines, cell and gene therapies, and sterile injectables.
Rapid Micro Biosystems primarily serves highly regulated industries such as pharmaceuticals, medical devices, and personal care products across North America, Europe, and Asia. Its solutions are critical for essential testing applications like environmental monitoring, water testing, bioburden analysis, and sterility release testing, all of which are vital for maintaining compliance and ensuring the integrity of products in these sectors.
```AI Analysis | Feedback
- Imagine an Illumina, but instead of sequencing DNA, they provide automated systems and consumables for detecting microbial contamination in pharmaceutical and medical device manufacturing.
- They're like the Cepheid (makers of the automated GeneXpert system) for industrial microbial quality control in manufacturing, bringing rapid, automated pathogen detection to factories instead of clinics.
AI Analysis | Feedback
- Growth Direct System: An automated system designed for rapid microbial detection in quality control workflows.
- Proprietary Consumables: Specialized materials essential for the operation of the Growth Direct System.
- Lab Information Management System (LIMS) Connection Software: Software that integrates the Growth Direct System with existing laboratory data management systems.
- Installation and Verification Services: Services provided for the setup, installation, and confirmation of the proper functioning of the Growth Direct System.
- Technical Training Services: Educational services offered to customers on the operation and maintenance of the Growth Direct System.
- Customer Support and Validation Services: Comprehensive support and validation assistance provided for the Growth Direct Platform.
AI Analysis | Feedback
- Pharmaceutical (including those producing biologics, vaccines, cell and gene therapies, and sterile injectables)
- Medical devices
- Personal care products
AI Analysis | Feedback
AI Analysis | Feedback
Robert Spignesi, President & CEO
Robert Spignesi has over 20 years of leadership experience, having served as Vice President and General Manager, Americas, for the Microbiology Division of Thermo Fisher Scientific. He was also the VP of Global Strategy, Marketing, and Business Development for Fisher Scientific. Additionally, he held senior positions at McKesson Corporation and its affiliates, including EVP Operations and Development and National Vice President of Sales and Business Development. Earlier in his career, Mr. Spignesi was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army.
Sean Wirtjes, Chief Financial Officer
Sean Wirtjes possesses over 30 years of broad financial experience in the healthcare and technology industries. Most recently, he was the Vice President, Finance and Controller of Asia Pacific, Middle East and Africa (AMEA) for Boston Scientific, a medical device manufacturer. Prior to that, he served as Vice President of Investor Relations at Boston Scientific and held progressive roles at Varian, Inc., including Vice President and Controller and Vice President, Finance and Treasurer. Mr. Wirtjes also served as Corporate Controller at Quova and began his career with PricewaterhouseCoopers, where he served emerging, high-growth clients across the healthcare and technology industries.
John Wilson, Chief Operating Officer
John Wilson brings over 20 years of experience from Medtronic and Becton Dickinson, most recently as the Vice President of Global Operations. He has held multiple leadership positions in quality, operational excellence, global operations, product development, and direct day-to-day plant management activities. Mr. Wilson also served in the U.S. Army.
James Xu, Senior VP Legal & Secretary
James Xu leads the global legal function at Rapid Micro Biosystems. Previously, he was a Partner in the life sciences business unit at Goodwin Procter LLP, a global law firm. During his 13 years at Goodwin, Mr. Xu advised numerous innovative and high-growth emerging companies in the healthcare industry, focusing on capital markets, corporate finance, public company reporting, and governance.
Todd Ballantyne, VP Research & Development
Todd Ballantyne has over 30 years of research and development experience in complex electro-mechanical systems for industries including life sciences, medical devices, machine vision, and defense. He previously led the Rapid Micro Biosystems software and vision teams. Before joining the company, Mr. Ballantyne led the Medtronic Hugo surgical robotics software team and the DEKA R&D Vivia hemodialysis systems team. He is a named inventor on patents related to computer backplane networking and surgical robotic arm control.
AI Analysis | Feedback
-
Persistent Unprofitability and Financial Health Challenges: Rapid Micro Biosystems has consistently reported significant net losses and negative operating and net margins, resulting in an accumulated deficit of $522.4 million as of December 31, 2025. The company is also experiencing cash burn, which raises concerns about its long-term financial sustainability. A low Piotroski F-Score and Altman Z-Score further indicate potential operational challenges and financial distress.
-
Barriers to Adoption of Rapid Microbial Methods (RMMs): Despite strong interest (93% of surveyed participants) in rapid sterility testing, the actual adoption rate of Rapid Microbial Methods (RMMs), including Rapid Micro Biosystems' Growth Direct system, remains relatively low at 28%. The primary hurdles hindering widespread adoption are the high cost of instruments and tests, the perceived complexity of the validation process, and the training requirements associated with new systems.
-
Reliance on Large Multi-System Orders: The company's revenue growth is significantly dependent on securing and executing large, multi-system orders from major pharmaceutical manufacturers. This dependency introduces volatility and uncertainty, as evidenced by management's guidance that the lower end of their 2026 revenue projection assumes no new large multi-system orders beyond those already announced. The timing and scale of these substantial purchases pose an ongoing execution risk for the business.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable markets for Rapid Micro Biosystems' main products and services are significant, primarily within the global microbial quality control (MQC) testing sector for pharmaceutical manufacturing.
Rapid Micro Biosystems estimates its total addressable market (TAM) for its Growth Direct systems to be approximately $5.0 billion globally. Additionally, the company projects the market for annual recurring sales of its consumables and services, addressable by its MQC testing solutions, to also be approximately $5.0 billion globally. These estimates are based on a total global sales opportunity of an estimated 10,000 Growth Direct systems and approximately 350 million tests conducted annually that could be addressed by their solutions.
The company operates within the broader global automated microbiology testing market, which was valued at approximately USD 7.62 billion in 2024 and is projected to grow to a substantial USD 21.71 billion by 2034, with a compound annual growth rate (CAGR) of around 10.71% from 2025 to 2034.
Specifically for the pharmaceutical microbiology quality control (QC) testing market, which directly aligns with Rapid Micro Biosystems' offerings, the global market size was valued at USD 12.18 billion in 2024 and is projected to reach USD 40.85 billion by 2035, growing at a CAGR of 12.9%. North America held the largest share of this market, accounting for 39.10% in 2025.
AI Analysis | Feedback
Rapid Micro Biosystems (RPID) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and market trends:
- Accelerated Growth Direct System Placements: The company anticipates significant growth from the increased placement of its Growth Direct systems. Management has provided guidance for 30 to 38 system placements in 2026, building on strong commercial momentum, including multi-system orders from major pharmaceutical partners like Amgen and Samsung Biologics. These enterprise-level adoptions by larger biopharmaceutical manufacturers are crucial for expanding the installed base globally.
- Expansion of Recurring Revenue from Consumables and Services: As the installed base of Growth Direct systems grows, the demand for proprietary consumables and comprehensive customer support and validation services is also expected to increase. Recurring revenue from these sources is already a significant portion of total revenue and is projected to expand, ensuring a consistent revenue stream.
- Launch of New Product Innovations, Particularly Analytics Software: Rapid Micro Biosystems plans to introduce new product innovations, specifically in analytics software. A next-generation, cloud-enabled software platform is slated for release in late 2026, which is designed to offer deeper insights and faster decision-making capabilities for global quality and manufacturing operations, thereby enhancing customer value and driving new revenue.
- Strategic Partnerships and International Market Expansion: The ongoing collaboration with MilliporeSigma is expected to play a meaningful role in contributing to system placements in 2026, especially through specialist training and demo lab setups in Europe and Asia. This partnership facilitates broader market penetration and geographic expansion.
- Benefiting from Industry Trends in Onshoring and Automation: Broader industry trends, such as the increasing focus on onshoring manufacturing and the growing demand for automation within pharmaceutical production, are anticipated to serve as significant tailwinds for Rapid Micro Biosystems. These trends underscore the critical need for efficient microbial quality control solutions, aligning with the company's core offerings.
AI Analysis | Feedback
Capital Allocation Decisions for Rapid Micro Biosystems (RPID)
Share Issuance
- Rapid Micro Biosystems completed its initial public offering (IPO) on July 14, 2021, issuing 7,920,000 shares of Class A common stock at $20.00 per share.
- The IPO generated expected gross proceeds of $158.4 million for the company.
- Additionally, underwriters were granted a 30-day option to purchase up to an extra 1,188,000 shares of Class A common stock at the IPO price.
Inbound Investments
- In August 2025, Rapid Micro Biosystems secured a five-year, $45 million term loan facility from Trinity Capital Inc.
- At the close of this facility, $20 million was funded.
- This capital influx is intended to strengthen the company's financial position and support its objectives for long-term revenue growth, gross margin expansion, and shareholder value.
Capital Expenditures
- Capital expenditures for the fourth quarter of 2025 amounted to $0.1 million.
- For the second quarter of 2025, capital expenditures were $0.4 million.
- The company anticipates capital expenditures of $2 million for the full year 2026, likely focused on operational scaling, including manufacturing, service, and research and development capabilities to support the Growth Direct platform.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Rapid Micro Biosystems Earnings Notes | 12/16/2025 | |
| Would You Still Hold Rapid Micro Biosystems Stock If It Fell 30%? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 175.50 |
| Mkt Cap | 27.0 |
| Rev LTM | 12,697 |
| Op Inc LTM | 1,770 |
| FCF LTM | 1,724 |
| FCF 3Y Avg | 1,676 |
| CFO LTM | 2,219 |
| CFO 3Y Avg | 2,163 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.9% |
| Rev Chg 3Y Avg | 1.2% |
| Rev Chg Q | 5.7% |
| QoQ Delta Rev Chg LTM | 1.3% |
| Op Inc Chg LTM | 9.6% |
| Op Inc Chg 3Y Avg | -3.5% |
| Op Mgn LTM | 12.8% |
| Op Mgn 3Y Avg | 12.4% |
| QoQ Delta Op Mgn LTM | 0.7% |
| CFO/Rev LTM | 17.5% |
| CFO/Rev 3Y Avg | 18.6% |
| FCF/Rev LTM | 14.0% |
| FCF/Rev 3Y Avg | 15.2% |
Price Behavior
| Market Price | $2.05 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 07/15/2021 | |
| Distance from 52W High | -56.2% | |
| 50 Days | 200 Days | |
| DMA Price | $2.03 | $3.04 |
| DMA Trend | down | down |
| Distance from DMA | 0.9% | -32.6% |
| 3M | 1YR | |
| Volatility | 65.5% | 87.7% |
| Downside Capture | 307.00 | 296.08 |
| Upside Capture | 169.81 | 169.80 |
| Correlation (SPY) | 32.4% | 27.5% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.33 | 0.77 | 1.26 | 1.77 | 1.84 | 1.22 |
| Up Beta | 0.78 | 0.43 | 1.38 | 1.69 | 1.06 | 1.00 |
| Down Beta | -0.80 | -0.22 | -0.38 | 2.65 | 2.02 | 1.34 |
| Up Capture | -28% | -8% | 56% | 83% | 166% | 237% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 6 | 14 | 26 | 56 | 114 | 344 |
| Down Capture | 128% | 230% | 266% | 190% | 178% | 107% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 21 | 30 | 62 | 124 | 368 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPID | |
|---|---|---|---|---|
| RPID | -41.0% | 87.3% | -0.22 | - |
| Sector ETF (XLV) | 20.3% | 15.7% | 0.98 | 21.6% |
| Equity (SPY) | 22.1% | 12.5% | 1.31 | 27.5% |
| Gold (GLD) | 23.5% | 27.8% | 0.75 | 24.1% |
| Commodities (DBC) | 23.6% | 18.7% | 0.99 | 3.0% |
| Real Estate (VNQ) | 13.4% | 13.9% | 0.67 | 15.2% |
| Bitcoin (BTCUSD) | -42.5% | 42.8% | -1.17 | 22.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPID | |
|---|---|---|---|---|
| RPID | -37.3% | 87.4% | -0.15 | - |
| Sector ETF (XLV) | 6.5% | 14.9% | 0.25 | 19.4% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 24.4% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 8.9% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | -1.0% |
| Real Estate (VNQ) | 2.9% | 18.9% | 0.05 | 17.6% |
| Bitcoin (BTCUSD) | 13.8% | 53.4% | 0.44 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RPID | |
|---|---|---|---|---|
| RPID | -20.8% | 87.4% | -0.15 | - |
| Sector ETF (XLV) | 10.3% | 16.6% | 0.51 | 19.4% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 24.4% |
| Gold (GLD) | 11.6% | 16.1% | 0.59 | 8.9% |
| Commodities (DBC) | 6.0% | 18.0% | 0.26 | -1.0% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.21 | 17.6% |
| Bitcoin (BTCUSD) | 58.6% | 66.2% | 0.99 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/16/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | -6.5% | -19.0% | -29.0% |
| 3/12/2026 | -21.8% | -38.8% | -51.6% |
| 1/13/2026 | 21.1% | 51.6% | 25.2% |
| 11/7/2025 | 12.7% | 62.2% | 41.1% |
| 8/12/2025 | -17.8% | -18.7% | -7.7% |
| 5/9/2025 | 25.7% | 24.9% | 44.5% |
| 2/28/2025 | -7.9% | -20.8% | -19.0% |
| 11/1/2024 | 1.9% | 14.8% | -7.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 9 |
| # Negative | 15 | 15 | 15 |
| Median Positive | 7.4% | 14.8% | 18.3% |
| Median Negative | -7.9% | -18.7% | -13.7% |
| Max Positive | 25.7% | 62.2% | 44.5% |
| Max Negative | -21.8% | -38.8% | -51.6% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/13/2026 | -6.5% | -19.0% | -29.0% |
| 3/12/2026 | -21.8% | -38.8% | -51.6% |
| 1/13/2026 | 21.1% | 51.6% | 25.2% |
| 11/7/2025 | 12.7% | 62.2% | 41.1% |
| 8/12/2025 | -17.8% | -18.7% | -7.7% |
| 5/9/2025 | 25.7% | 24.9% | 44.5% |
| 2/28/2025 | -7.9% | -20.8% | -19.0% |
| 11/1/2024 | 1.9% | 14.8% | -7.4% |
| 8/2/2024 | 17.3% | 25.4% | 25.4% |
| 5/3/2024 | -10.1% | -18.7% | -18.2% |
| 3/1/2024 | -10.9% | -11.0% | -12.7% |
| 1/10/2024 | -5.0% | -2.0% | -5.9% |
| 11/3/2023 | 7.4% | -3.0% | 8.9% |
| 8/4/2023 | -2.1% | -0.1% | 2.1% |
| 5/5/2023 | 2.2% | 1.1% | 18.3% |
| 3/3/2023 | 6.0% | 6.0% | 12.0% |
| 1/11/2023 | -2.1% | -0.7% | -11.3% |
| 11/10/2022 | 4.2% | 3.8% | -23.7% |
| 8/12/2022 | -6.1% | -22.2% | -13.7% |
| 5/10/2022 | -7.1% | -20.4% | -8.1% |
| 3/4/2022 | -5.6% | 3.0% | 9.3% |
| 1/10/2022 | -21.2% | -20.4% | -7.2% |
| 11/12/2021 | -19.6% | -24.1% | -51.2% |
| 8/26/2021 | -9.4% | -14.6% | -16.1% |
| SUMMARY STATS | |||
| # Positive | 9 | 9 | 9 |
| # Negative | 15 | 15 | 15 |
| Median Positive | 7.4% | 14.8% | 18.3% |
| Median Negative | -7.9% | -18.7% | -13.7% |
| Max Positive | 25.7% | 62.2% | 44.5% |
| Max Negative | -21.8% | -38.8% | -51.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/12/2026 | 10-K |
| 09/30/2025 | 11/07/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/28/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/02/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/09/2023 | 10-Q |
| 12/31/2022 | 03/10/2023 | 10-K |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
| 12/31/2021 | 03/24/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/27/2021 | 10-Q |
| 03/31/2021 | 07/12/2021 | S-1/A |
Insider Activity
Updated 6/2/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wilson, John J Addington | CHIEF OPERATING OFFICER | Direct | Sell | 3122026 | 4.32 | 9,603 | 41,467 | 1,367,810 | Form |
| 2 | Wirtjes, Sean M | CHIEF FINANCIAL OFFICER | Direct | Sell | 3122026 | 4.32 | 7,480 | 32,299 | 2,401,701 | Form |
| 3 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 3122026 | 4.11 | 17,922 | 73,686 | 4,809,830 | Form |
| 4 | Wilson, John J Addington | CHIEF OPERATING OFFICER | Direct | Sell | 2202026 | 3.92 | 5,403 | 21,196 | 1,280,330 | Form |
| 5 | Wirtjes, Sean M | CHIEF FINANCIAL OFFICER | Direct | Sell | 2202026 | 3.92 | 17,254 | 67,687 | 2,211,293 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Wilson, John J Addington | CHIEF OPERATING OFFICER | Direct | Sell | 3122026 | 4.32 | 9,603 | 41,467 | 1,367,810 | Form |
| 2 | Wirtjes, Sean M | CHIEF FINANCIAL OFFICER | Direct | Sell | 3122026 | 4.32 | 7,480 | 32,299 | 2,401,701 | Form |
| 3 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 3122026 | 4.11 | 17,922 | 73,686 | 4,809,830 | Form |
| 4 | Wilson, John J Addington | CHIEF OPERATING OFFICER | Direct | Sell | 2202026 | 3.92 | 5,403 | 21,196 | 1,280,330 | Form |
| 5 | Wirtjes, Sean M | CHIEF FINANCIAL OFFICER | Direct | Sell | 2202026 | 3.92 | 17,254 | 67,687 | 2,211,293 | Form |
| 6 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 2202026 | 3.89 | 38,327 | 148,912 | 4,614,843 | Form |
| 7 | Wilson, John J Addington | CHIEF OPERATING OFFICER | Direct | Sell | 2102026 | 3.78 | 4,610 | 17,438 | 975,059 | Form |
| 8 | Wirtjes, Sean M | CHIEF FINANCIAL OFFICER | Direct | Sell | 2102026 | 3.78 | 6,027 | 22,798 | 1,830,554 | Form |
| 9 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 2102026 | 3.78 | 12,840 | 48,570 | 3,639,324 | Form |
| 10 | Longitude, Capital Partners Ii, Llc | Held by Longitude Prime Fund, L.P. | Sell | 2062026 | 3.88 | 49,000 | Form | |||
| 11 | Longitude, Capital Partners Ii, Llc | Held by Longitude Prime Fund, L.P. | Sell | 2032026 | 4.24 | 27,500 | 116,641 | 207,834 | Form | |
| 12 | Longitude, Capital Partners Ii, Llc | Held by Longitude Prime Fund, L.P. | Sell | 2032026 | 4.25 | 27,500 | 116,765 | 324,819 | Form | |
| 13 | Longitude, Capital Partners Ii, Llc | Held by Longitude Prime Fund, L.P. | Sell | 2032026 | 4.54 | 46,000 | 209,001 | 472,524 | Form | |
| 14 | Longitude, Capital Partners Ii, Llc | Held by Longitude Venture Partners II, L.P. | Sell | 2032026 | 4.06 | 7,739 | 31,451 | 16,374,852 | Form | |
| 15 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 7152025 | 3.32 | 11,881 | 39,481 | 3,225,138 | Form |
| 16 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 7152025 | 3.33 | 11,874 | 39,499 | 3,184,412 | Form |
| 17 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 7102025 | 3.40 | 11,617 | 39,475 | 3,207,763 | Form |
| 18 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 7102025 | 3.51 | 11,247 | 39,480 | 3,161,317 | Form |
| 19 | Spignesi, Robert G JR | PRESIDENT AND CEO | Direct | Sell | 7102025 | 3.51 | 10,824 | 38,021 | 3,114,662 | Form |
Investor Activity (13F)
Updated Jul 13, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank and community-bank filers are excluded.
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.